Trial · NCT07032714
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT07032714, Phase 1, Recruiting, Massachusetts General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma. Trials, record NCT07032714. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07032714
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
- NCT number
- NCT07032714
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Talquetamab, Mezigdomide, Dexamethasone
- First posted
- 2025-06-24
- Last updated
- 2026-04-13
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended Dose | Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment) | To determine the recommended dose and schedule of mezigdomide and talquetamab in triple class exposed, relapsed and refractory multiple myeloma (RRMM), the dose level where 2 of 6 participants experience a DLT is considered the maximum tolerated dose. The dose level below this will be considered a recommended phase 2 dose. Or if dose level 2 is reached (mezigdomide 1 mg po for 21 out of 28 days) and there are ≤1 DLTs out of 6 participants, then dose level 2 will be considered the recommended phase 2 dose. Data from the secondary outcomes (frequency of adverse events, serious adverse events, and dose-limiting toxicities) will be used for this outcome. |
| Secondary | Frequency of adverse events | Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment) | Assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, the frequency of AEs will be tabulated by cohort and dose. |
| Secondary | Frequency of serious adverse events | Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment) | Assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, the frequency of serious AEs will be tabulated by cohort and dose. |
| Secondary | Frequency of dose-limiting toxicities (DLT) | Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment) | Unacceptable toxicity will be defined as grade 3-4 CRS, grade 3-4 ICANS, and grade 4, treatment-related, non-hematologic adverse events. Assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 when applicable. The frequency and type of DLTs will be tabulated by cohort and dose. |
| Secondary | Overall response rate (ORR) | Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal) | Response rate will be according to IMWG criteria. Overall response rate is rate of patients achieving partial response or better. |
| Secondary | Progression Free Survival (PFS) | Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal) | Progression-free survival (PFS) is defined as the time from start of treatment to disease progression or death from any cause. Patients who have not progressed or died are censored at the date last known progression-free. Response will be according to IMWG criteria. PFS will be determined from first dose of study drug, according to Kaplan-Meier methodology. |
| Secondary | Overall Survival (OS) | Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal) | Overall survival (OS) is defined as the time from start of treatment to death due to any cause or censored at date last known alive. Response will be according to IMWG criteria. OS will be determined from first dose of study drug, according to Kaplan-Meier methodology. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07032714
GET https://conductscience.org/api/trials/v1/NCT07032714/registered